HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis.

AuthorsE Rallis, G Papatheodorou, E Bimpakis, D Butanska, P Menounos, P Papadakis
JournalJournal of the European Academy of Dermatology and Venereology : JEADV (J Eur Acad Dermatol Venereol) Vol. 22 Issue 4 Pg. 523-5 (Apr 2008) ISSN: 1468-3083 [Electronic] England
PMID18363932 (Publication Type: Case Reports, Letter)
Chemical References
  • Dermatologic Agents
  • Isotretinoin
Topics
  • Adult
  • Dermatologic Agents (administration & dosage, therapeutic use)
  • Epidermodysplasia Verruciformis (drug therapy)
  • Facial Dermatoses (drug therapy)
  • Humans
  • Isotretinoin (administration & dosage, therapeutic use)
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: